Rosetta Genomics to Present at LD MICRO “Main Event” Micro-Cap Growth Conference on December 3, 2014
November 25 2014 - 8:00AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, today announced
that Company management will participate in the upcoming LD MICRO
“Main Event” Micro-Cap Growth Conference taking place from December
2-4, 2014 in Los Angeles. Kenneth A. Berlin, President and CEO of
Rosetta Genomics, will present a corporate overview on Wednesday,
December 3, 2014 at 5:00 p.m. PST (8:00 p.m. EST).
Mr. Berlin’s presentation will be webcast live on the internet
and can be accessed at the Investors section of the Company’s
website at www.rosettagenomics.com, where it will also be archived
for 90 days.
About Rosetta Genomics
Founded in 2000, Rosetta’s integrative research platform
combining bioinformatics and state-of-the-art laboratory processes
has led to the discovery of hundreds of biologically validated
novel human microRNAs. Building on its strong patent position and
proprietary platform technologies, Rosetta is working on the
application of these technologies in the development and
commercialization of a full range of microRNA-based diagnostic
tools and therapeutics. Rosetta currently commercializes a full
range of microRNA-based molecular diagnostics. Rosetta’s cancer
testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. For more
information, please visit www.rosettagenomics.com.
Rosetta Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without limitation,
statements relating to Rosetta monetizing its leading microRNA
platform and expertise, Rosetta developing and commercializing
diagnostic tools, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a
result of various important factors, including those risks more
fully discussed in the "Risk Factors" section of Rosetta’s Annual
Report on Form 20-F for the year ended December 31, 2013 as
filed with the SEC. In addition, any forward-looking statements
represent Rosetta’s views only as of the date of this release and
should not be relied upon as representing its views as of any
subsequent date. Rosetta does not assume any obligation to update
any forward-looking statements unless required by law.
Rosetta Genomics:Ken Berlin, 609-419-9000, ext.
1326President & CEOinvestors@rosettagenomics.comorRosetta
Genomics Investor:LHAAnne Marie Fields,
212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024